TABLE 2

Clinical characteristics of subjects who underwent both glucose clamp and FSIVGTT studies

NonobeseObeseType 2 diabetesHypertension
n26141127
Age (years)31 ± 442 ± 347 ± 345 ± 2
Sex (M/F)13/136/87/411/16
BMI (kg/m2)24 ± 139 ± 234 ± 231 ± 1
Fasting insulin (μU/ml)6.4 ± 1.715.9 ± 2.513.6 ± 1.310.8 ± 1.0
Fasting glucose (mg/dl)85 ± 489 ± 2166 ± 1983 ± 2
Blood pressure (mmHg)121 ± 6/69 ± 3134 ± 3/76 ± 2130 ± 4/76 ± 2152 ± 3/88 ± 2
Total cholesterol (mg/dl)171 ± 16195 ± 9204 ± 11206 ± 8
LDL (mg/dl)88 ± 12112 ± 8118 ± 6142 ± 7
HDL (mg/dl)47 ± 642 ± 243 ± 454 ± 3
Triglycerides (mg/dl)124 ± 27146 ± 18223 ± 48139 ± 14
HbA1c (%)5.5 ± 0.26.0 ± 0.27.4 ± 0.65.7 ± 0.1
  • Data are means ± SE (n = 78). BMI: P < 0.001 for obese, diabetic, and hypertensive subjects, respectively, vs. normal nonobese subjects. Fasting insulin: P < 0.001 for obese, diabetic, and hypertensive subjects, respectively, vs. normal nonobese subjects. Total cholesterol: P < 0.05 for obese, diabetic, and hypertensive subjects, respectively, vs. normal nonobese subjects. LDL: P < 0.01 for obese, diabetic, and hypertensive subjects, respectively, vs. normal nonobese subjects.